As of February 2015, "Amarantus BioScience Holdings (OTCQB:AMBS) and Anavex Life Sciences (OTCQX:AVXL) signed a biomarker services agreement in which Amarantus will evaluate the pharmacodynamic effect of ANAVEX 2-73 and ANAVEX PLUS on the expression of the biomarker CD69 in specific sub-populations of peripheral blood lymphocytes, using Amarantus’ proprietary Alzheimer’s blood diagnostic LymPro Test" in an expected PhaseIII trial.
As of June 2015, AMBS announced two late-breaking abstracts on the LymPro Test® have been accepted for presentation at the 2015 Alzheimer's Association International Conference. AMBS will present data from two studies on its LymPro blood-based diagnostic assay for Alzheimer's disease (AD) during AAIC poster sessions in abstracts entitled:
"The LymPro Test®: A Biomarker for Alzheimer's Disease Using Blood Samples from Clinically Diagnosed Alzheimer's Disease and Cognitively Intact Subjects."
It appears this data was already presented at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PDTM 2015) held March 18-22, 2015, in Nice, France.
"The LymPro Test®: A Fit for Purpose Validation of a Flow Cytometric Assay to Assess Lymphocyte Proliferation in Peripheral Blood Lymphocytes in Alzheimer's Disease."
This later abstract appears new. Which indicates AMBS may not have been expecting to present this poster so soon. If this abstract is associated with something I am missing, please let me know.
In a February 2015 Anavex news release AMBS CEO stated, “We are pleased to assist Anavex, our first customer, in evaluating the potential of ANAVEX 2-73 and ANAVEX PLUS to increase CD69 expression using LymPro in blood derived from AD patients...Our premier diagnostics division, Amarantus Diagnostics, is well positioned to add value to pharmaceutical companies’ Alzheimer’s therapeutics programs by helping them better execute AD therapeutic clinical studies. We will assist companies by enriching the population of subjects enrolling in Alzheimer’s clinical studies, the key unmet need for therapeutic Alzheimer’s programs...We are currently in active discussions with both emerging and large pharma companies as we work to build a significant customer base for blood-based biomarker services in Alzheimer’s disease, with the ultimate shared goal of improving the current standard of care used to treat AD".
As I understand, cytometric detection is accomplished in part through CD69 expression.
Question: In your opinion, does the late breaking AMBS abstract suggest AMBS is ready to move forward in support of AVXLs PHIII trial? Given the fact the AVXL PhaseIIA is open label, is it possible AMBS is aware and preparing for AVXL's PIII? Is it even possible for AMBS to have an indication of the AVXL PhaseIIA trial data at this time?
Happy trading and God bless!
